Akari Therapeutics PLC (AKTX) versus The Competition Critical Review
Akari Therapeutics PLC (NASDAQ: AKTX) is one of 295 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare Akari Therapeutics PLC to related businesses based on the strength of its institutional ownership, risk, earnings, analyst recommendations, valuation, profitability and dividends.
Earnings & Valuation
This table compares Akari Therapeutics PLC and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Akari Therapeutics PLC||N/A||-$31.46 million||-23.94|
|Akari Therapeutics PLC Competitors||$260.16 million||$66.28 million||-6.28|
Akari Therapeutics PLC’s rivals have higher revenue and earnings than Akari Therapeutics PLC. Akari Therapeutics PLC is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
Akari Therapeutics PLC has a beta of -9.15, suggesting that its stock price is 1,015% less volatile than the S&P 500. Comparatively, Akari Therapeutics PLC’s rivals have a beta of 6.66, suggesting that their average stock price is 566% more volatile than the S&P 500.
This is a breakdown of current ratings and target prices for Akari Therapeutics PLC and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Akari Therapeutics PLC||0||1||2||0||2.67|
|Akari Therapeutics PLC Competitors||765||3039||11205||227||2.72|
Akari Therapeutics PLC presently has a consensus price target of $8.75, suggesting a potential upside of 103.02%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 36.85%. Given Akari Therapeutics PLC’s higher possible upside, research analysts clearly believe Akari Therapeutics PLC is more favorable than its rivals.
Institutional and Insider Ownership
27.0% of Akari Therapeutics PLC shares are held by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 61.8% of Akari Therapeutics PLC shares are held by insiders. Comparatively, 17.0% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This table compares Akari Therapeutics PLC and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Akari Therapeutics PLC||N/A||-77.39%||-55.94%|
|Akari Therapeutics PLC Competitors||-5,510.04%||-450.98%||-42.10%|
Akari Therapeutics PLC rivals beat Akari Therapeutics PLC on 8 of the 12 factors compared.
About Akari Therapeutics PLC
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome. Its lead drug, Coversin, a complement inhibitor, acts on complement C5, preventing release of C5a and formation of C5b-9. Coversin is a recombinant small protein derived from a protein discovered in the saliva of the Ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response. It is conducting Phase Ib clinical trial of Coversin. It focuses on rare and orphan diseases, including disease states spanning hematology, nephrology, transplantation, neurology and ophthalmology.
Receive News & Stock Ratings for Akari Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics PLC and related stocks with our FREE daily email newsletter.